SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center
- PMID: 34072058
- PMCID: PMC8228790
- DOI: 10.3390/vaccines9060560
SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center
Abstract
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have been reported after SARS-CoV2 RNA vaccines. Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. This risk is estimated at 1/1,000,000 in the context of vaccine safety surveillance programs. The COVID-19 vaccination is rolling-out vastly in different courtiers and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care. The here presented recommendations and follow-up from the French allergy community and the Montpellier WHO Collaborating Center in order to support the vaccination program and intends to support to healthcare professionals in their daily basis.
Keywords: COVID-19; SARS-CoV-2 vaccination; allergy; anaphylaxis; recommendations; vaccine.
Conflict of interest statement
The authors declare that they do not have conflict of interests related to the contents of this article.
Figures
References
-
- World Health Organization Website. [(accessed on 13 April 2021)]; Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on....
-
- Centers of Disease Control Website. [(accessed on 20 May 2021)]; Available online: https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm.
-
- Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19. [(accessed on 14 January 2021)];2020 Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-an....
-
- U.S. FDA Takes Additional Action in Fight Against COVID-19 by Issuing Emergency Use Authorization for Second COVID-19 Vaccine. [(accessed on 14 January 2021)];2020 Available online: https://www.fda.gov/news-events/press-announcements/fda-takes-additional....
-
- Moderna Press Release. [(accessed on 14 January 2021)];2021 Available online: https://investors.modernatx.com/news-releases.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
